Absci Corp Dossier - Source-backed chat

Absci Corp

ABSINASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.93

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $10.77Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $1.8B

Enterprise Value $1.7B

Shares Outstanding 166M diluted

Next Earnings Date12 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Absci Corp is a clinical-stage biopharmaceutical company pioneering generative AI drug creation. By combining advanced machine learning models with high-throughput wet-lab validation, Absci accelerates antibody design from concept to clinic. The investment thesis centers on the rapid clinical validation of its lead asset, ABS-201 (an anti-PRLR antibody), which is currently in a Phase 1/2a trial for androgenetic alopecia (hair loss) and is poised to enter Phase 2 for endometriosis in late 2026. With a robust cash runway extending into H1 2028 and high-profile partnerships (such as AstraZeneca), Absci represents a high-upside play on the industrialization of AI-driven biologics.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets9 analysts · as of 18 Aug 2026

Low · most bearish analyst$10.00

Mean target$13.89

High · most bullish analyst$17.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$10.0015%

ABS-201 clinical data shows high variability, safety concerns, or insufficient efficacy in hair regrowth, leading to a significant delay or termination of the program. Partner program revenues remain depressed due to milestone timing, and the company is forced to raise dilutive capital earlier than expected, driving the stock down toward its historical support levels.

Base CaseCentral scenario

$13.8960%

Matches the consensus mean

ABS-201 demonstrates favorable safety, tolerability, and expected pharmacokinetic profiles in the HEADLINE trial, with interim hair regrowth data in H2 2026 supporting its therapeutic potential. Absci successfully signs at least one new major pharma partnership in 2026, maintaining its cash runway into 2028. The stock moves steadily toward the consensus analyst price target of $9.61 as clinical milestones are met.

Bull CaseUpside scenario

$17.0025%

ABS-201 delivers outstanding 13-week and 26-week hair regrowth data, demonstrating superior efficacy and a highly convenient dosing profile (2-3 injections over 6 months) compared to existing daily treatments. This triggers a lucrative global co-development partnership with a major pharmaceutical company, unlocking substantial upfront milestones. Simultaneously, the Phase 2 trial in endometriosis initiates smoothly, validating the platform's multi-indication potential and driving the stock toward the high analyst target of $15.00.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Proprietary Integrated Drug Creation platform that screens billions of cells weekly, reducing antibody design-to-validation timelines to as little as six weeks.
Lead asset ABS-201 targets large, underserved markets in androgenetic alopecia (estimated $5B+ US potential) and endometriosis.
Strong liquidity position with $125.7M in cash and marketable securities as of Q1 2026, providing a runway into H1 2028.
Established validation through high-profile collaborations, including a major oncology-focused partnership with AstraZeneca.

Key Investment Risks

High clinical development risk, as ABS-201 is awaiting its first major human efficacy readouts.
Significant revenue volatility due to reliance on the timing of partner milestones.
Intense competition in the AI-driven drug discovery space from both established computational players and emerging biotech platforms.

Thesis Invalidation Triggers

Failure of ABS-201 to meet safety or primary pharmacokinetic endpoints in the HEADLINE trial.
Inability to initiate the Phase 2 endometriosis trial in Q4 2026 due to regulatory or clinical delays.
A severe contraction in cash runway caused by unexpected acceleration in R&D burn rates without offsetting partner milestones.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.